Targeting of the peptide hormone relaxin to injured mouse liver, via a nanoparticle/gene therapy approach, switches pro-fibrotic hepatic macrophages to a restorative phenotype that orchestrates tissue repair.
This is a preview of subscription content, log in via an institution to check access.
References
Hu, M. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-020-00836-6 (2020).
Samuel, C. S. et al. Ann. N. Y. Acad. Sci. 1041, 173–81 (2005).
Fallowfield, J. A. et al. Hepatology 59, 1492–1504 (2014).
Lee, K.-C. et al. Lab. Investig. 99, 1203–1216 (2019).
Bennett, R. G., Heimann, D. G., Singh, S., Simpson, R. L. & Tuma, D. J. Liver Int. 34, 416–426 (2014).
Kaftanovskaya, E. M. et al. FASEB J. 33, 12435–12446 (2019).
Kim, J. K. et al. J. Gene Med. 18, 16–26 (2016).
Nagórniewicz, B. et al. Nanomedicine 17, 106–118 (2019).
Ramachandran, P. et al. Proc. Natl Acad. Sci. USA 109, E3186–E3195 (2012).
Chen, L. et al. Oncotarget 8, 21044–21053 (2017).
Ramachandran, P. et al. Nature 575, 512–518 (2019).
Pellicoro, A., Ramachandran, P., Iredale, J. & Fallowfield, J. A. Nat. Rev. Immunol. 14, 181–194 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they are bound by confidentiality agreements that prevent them from disclosing their competing interests in this work.
Rights and permissions
About this article
Cite this article
Fallowfield, J.A., Ramachandran, P. A relaxin-based nanotherapy for liver fibrosis. Nat. Nanotechnol. 16, 365–366 (2021). https://doi.org/10.1038/s41565-020-00832-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41565-020-00832-w
- Springer Nature Limited
This article is cited by
-
Oral delivery of ferroptosis inducers for effective treatment of hepatic fibrosis
Nano Research (2024)